KELLE AIKIN: Open Payments
NPI 1982860078 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$172 in 6 payments from 6 companies in 2025. Trend: 2023 $33 · 2024 $177 · 2025 $172
Food & beverage: $172
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 1 | $38 |
| E.R. Squibb & Sons, L.L.C. | 1 | $36 |
| Luye Pharma (USA) Ltd. | 1 | $27 |
| Neurocrine BioSciences, Inc. | 1 | $25 |
| Alkermes, Inc. | 1 | $23 |
| ABBVIE INC. | 1 | $23 |
Products named: UZEDY, COBENFY, ERZOFRI EXTENDED-RELEASE, INGREZZA, ARISTADA, VRAYLAR.
Industry payments across NV — which companies pay providers there.
